Health Improved OS With Hyperfractionated RT in Recurrent Nasopharyngeal Carcinoma James Pereira Mar 21, 2023 Compared with standard… Read More...
Health Junshi Biosciences and Coherus Share Update on the FDA Review of the Biologics License Application… James Pereira Dec 25, 2022 - FDA has been unable to travel to China to conduct the required site inspection resulting in delayed action on the BLA… Read More...
Health COVID vaccination improves effectiveness of cancer treatment, study finds: Clinical study on… James Pereira Nov 9, 2022 Patients with nasopharyngeal cancer are often treated with drugs that activate their immune system against the tumor.… Read More...
Health Radiation Alone May Suffice for Some Nasopharyngeal Cancer James Pereira Jun 7, 2022 CHICAGO – In selected patients with nasopharyngeal carcinoma,… Read More...
Health PD-1 Inhibition Shows ‘Clear’ Benefit in Nasopharyngeal Carcinoma James Pereira Apr 21, 2022 Adding the PD-1 inhibitor… Read More...
Health Junshi Biosciences and Coherus Present Results of Phase 3 Study of Toripalimab in First Line… James Pereira Apr 9, 2022 SHANGHAI, China, and REDWOOD CITY, Calif., April 09, 2022 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd … Read More...
Health Triplet Induction Regimen Bests Doublet for Nasopharyngeal Carcinoma James Pereira Mar 26, 2022 Induction chemotherapy with… Read More...
Health Lower Neck-Sparing RT Succeeds in Nasopharyngeal Carcinoma James Pereira Mar 3, 2022 Use of elective ipsilateral… Read More...
Health Junshi Biosciences Announces Approval of Supplemental New Drug Application by NMPA for Toripalimab… James Pereira Nov 30, 2021 SHANGHAI, China, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX:… Read More...
Health Coherus and Junshi Biosciences Announce Completion of Rolling BLA Submission to U.S. FDA for… James Pereira Sep 1, 2021 SHANGHAI, China, and REDWOOD CITY, Calif., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd.… Read More...